EIF4H — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL148606	0.65	4/20
SCHEMBL116767	0.61	4/20
SCHEMBL148355	0.56	4/20
SCHEMBL1353280	0.55	4/20
SCHEMBL827107	0.49	4/20
SCHEMBL995824	0.77	3/20
SCHEMBL394478	0.60	3/20
SCHEMBL1133969	0.52	3/20
SCHEMBL1381127	0.50	3/20
SCHEMBL1468153	0.50	3/20
SCHEMBL349575	0.49	3/20
SCHEMBL349576	0.49	3/20
SCHEMBL827255	0.46	3/20
SCHEMBL566193	0.44	3/20
SCHEMBL1127233	0.44	3/20
Hydrazinecarboxamide (SCHEMBL1464164)	0.43	3/20
Ivacaftor (SCHEMBL417309)	0.39	3/20
SCHEMBL1579073	0.39	3/20
SCHEMBL1132254	0.66	2/20
SCHEMBL1132255	0.66	2/20

Clinical trials — most relevant to EIF4H by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
Non-invasive Remote Ischemic PreConditioning (RIPC) in Free Flaps for Breast Reconstruction	nan	COMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a EIF4H binder may also engage these)

Protein	Name	Similarity
Q5XI72	—	1.000	Q5XI72 →
Q9WUK2	—	1.000	Q9WUK2 →
Q1JPH6	—	1.000	Q1JPH6 →
Q5RBR8	—	0.997	Q5RBR8 →
O14369	—	0.988	O14369 →
P78814	—	0.987	P78814 →
RBM3	RNA-binding protein 3	0.983	landscape →
A7VJC2	—	0.982	A7VJC2 →
O89086	—	0.982	O89086 →
Q14011	—	0.981	Q14011 →
P25555	—	0.981	P25555 →
Q5RF83	—	0.981	Q5RF83 →
Q01560	—	0.981	Q01560 →
P60826	—	0.980	P60826 →
W8E7I1	—	0.980	W8E7I1 →
Q28IQ9	—	0.980	Q28IQ9 →
Q9SAD7	—	0.980	Q9SAD7 →
Q9DED4	—	0.980	Q9DED4 →
Q28521	—	0.980	Q28521 →
Q9LIN3	—	0.979	Q9LIN3 →
Q5RBU8	—	0.979	Q5RBU8 →
P60824	—	0.979	P60824 →
P60825	—	0.979	P60825 →
Q32P51	—	0.978	Q32P51 →
Q9VHP0	—	0.978	Q9VHP0 →
P38922	—	0.978	P38922 →
Q9ZPX8	—	0.978	Q9ZPX8 →
Q94901	—	0.977	Q94901 →
Q925G0	—	0.977	Q925G0 →
Q8RWN5	—	0.977	Q8RWN5 →